Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pinuccia Valagussa

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Cancer Medicine|July 26, 2020
Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trialsMarc P E André, Patrice Carde, Simonetta Viviani, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2004
Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) studyMaura Massimino, Lorenza Gandola, Felice Giangaspero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerMarion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Nature|September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancerXiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerMatteo Dugo, Chiun-Sheng Huang, Daniel Egle, et al.
Lancet (London, England)|February 18, 2014
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Lijun Zhang, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2023
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS TrialGeorg Pfeiler, Dominik Hlauschek, Erica L Mayer, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Cancer Medicine|July 26, 2020
Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trialsMarc P E André, Patrice Carde, Simonetta Viviani, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2004
Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) studyMaura Massimino, Lorenza Gandola, Felice Giangaspero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerMarion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Nature|September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancerXiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerMatteo Dugo, Chiun-Sheng Huang, Daniel Egle, et al.
Lancet (London, England)|February 18, 2014
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Lijun Zhang, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2023
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS TrialGeorg Pfeiler, Dominik Hlauschek, Erica L Mayer, et al.
Pageof 6